Clinical Trial Record

Return to Clinical Trials

Ghrelin Levels in Pancreatic Cancer Patients


2004-04


2013-10


2015-09


72

Study Overview

Ghrelin Levels in Pancreatic Cancer Patients

The primary outcome measure for this study is plasma ghrelin level.

The primary outcome measure for this study is plasma ghrelin level, and the two primary comparison are: * Patients with cachexia versus patients without cachexia * Patients with cachexia versus healthy controls

  • Pancreatic Cancer
  • PROCEDURE: Blood draw
  • DMS 0405

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2005-09-22  

N/A  

2015-10-12  

2005-09-22  

N/A  

2015-10-14  

2005-09-26  

N/A  

2015-08  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
N/A


Allocation:
N/A


Interventional Model:
N/A


Masking:
N/A


Arms and Interventions

Participant Group/ArmIntervention/Treatment
: 1

Pancreatic cancer patients

PROCEDURE: Blood draw

  • One blood draw prior to first treatment
: 2

Healthy controls

PROCEDURE: Blood draw

  • One blood draw prior to first treatment
Primary Outcome MeasuresMeasure DescriptionTime Frame
To evaluate plasma ghrelin levels in patients with pancreatic cancer and compare with age matched controlsprior to treatment
Secondary Outcome MeasuresMeasure DescriptionTime Frame
To investigate the role of ghrelin in pathophysiology of cancer cachexiaprior to treatment
To generate hypotheses for future studies and treatment based on the findingsprior to treatment

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:
1

    Inclusion Criteria:

  • Histological or cytological proof of pancreatic adenocarcinoma
  • The control are will include healthy age-matched patients without cancer
  • The test arm will include patients with pancreatic cancer and they will divided into two groups: those with and without weight loss
  • Patients must have recovered from any major infections and/or surgical procedures

  • Exclusion Criteria:

  • Patients with other serious medical illness like congestive heart failure, thyroid disease,liver disease or renal failure - conditions that will alter their nutritional state
  • Patients on appetite stimulant and those receiving total parenteral nutrition
  • Patients who have undergone gastrectomy or those who have gastric ulcers
  • Patients receiving active chemotherapy
  • No prior malignancy except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer or for which patient has been disease free for at least five years.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.


    • PRINCIPAL_INVESTIGATOR: J Marc Pipas, MD, Dartmouth-Hitchcock Medical Center

    Publications

    The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

    General Publications

    No publications available